<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28914">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02730312</url>
  </required_header>
  <id_info>
    <org_study_id>XmAb14045-01</org_study_id>
    <nct_id>NCT02730312</nct_id>
  </id_info>
  <brief_title>PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies</brief_title>
  <official_title>A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®14045 in Patients With CD123-Expressing Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xencor, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chiltern International Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Xencor, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability of weekly intravenous
      (IV) administration of XmAb14045 and to determine the maximally tolerated dose (MTD) after
      the first dose, and then to determine the MTD after second and subsequent infusions.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) for first and subsequent infusions</measure>
    <time_frame>Baseline Day 1 through Day 56</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability as assessed by AEs, vital signs, physical exam findings, clinical laboratory safety assessments, and electrocardiogram (ECG) parameters, and incidence of treatment-emergent AEs</measure>
    <time_frame>Baseline Day 1 through Day 56</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Acute Myelogenous Leukemia</condition>
  <condition>B-cell Acute Lymphoblastic Leukemia</condition>
  <condition>Blastic Plasmacytoid Dendritic Cell Neoplasm</condition>
  <condition>Chronic Myeloid Leukemia, Blast Crisis</condition>
  <arm_group>
    <arm_group_label>XmAb14045</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>XmAb14045</intervention_name>
    <description>Administered IV weekly up to 8 weeks</description>
    <arm_group_label>XmAb14045</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of 1 of the following diseases:

          -  Primary or secondary AML (including erythroleukemia and eosinophilic leukemia, but
             excluding acute promyelocytic leukemia)

          -  B-cell ALL

          -  BPDCN

          -  CML in blast phase, resistant or intolerant to tyrosine kinase inhibitor therapy

          -  Patients with relapsed or refractory disease with no available standard therapy

          -  ECOG performance status 0-2

          -  Not a candidate for, or refusing treatment with hematopoietic stem cell
             transplantation

        Exclusion Criteria:

          -  Cytotoxic chemotherapy, radiotherapy, immunotherapy or investigational agent
             treatment within 2 weeks of first dose of study drug

          -  Prior therapy with CD123- or IL-3R-directed immunotherapies, including monospecific
             and bsAbs, immunoconjugates, or chimeric antigen receptor-modified T-cell therapy

          -  Failure to recover from Grade 3 or 4 toxicity from previous treatment (unrelated to
             malignant bone marrow involvement)

          -  Known uncontrolled central nervous system involvement by malignant disease

          -  White blood cell (WBC) count ≥10,000/mm3 or symptoms of leukostasis

          -  Diagnosis of promyelocytic leukemia

          -  Aspartate aminotransferase or alanine aminotransferase at screening &gt;3.0 x upper
             limit of normal (ULN) unless considered due to leukemic organ involvement

          -  Bilirubin &gt;1.5 x ULN, unless prior diagnosis and documentation of leukemic organ
             involvement, ongoing hemolysis, or Gilbert's syndrome

          -  Serum creatinine &gt;2.0 x ULN, or estimated creatinine clearance &lt;40mL/min

          -  History or evidence of a clinically unstable/uncontrollable disorder, condition or
             disease other than primary malignancy, that in the opinion of the Investigator would
             pose a risk to the patient safety or interfere with the study evaluation

          -  Evidence of any active, uncontrolled bacterial, viral, parasitic fungal infections
             within 1 week of first dose of study drug

          -  Positive test for human immunodeficiency virus (HIV) -I or -II antibodies, hepatitis
             B surface antigen or core antibody, or hepatitis C virus antibody
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wayne Saville, MD</last_name>
    <role>Study Director</role>
    <affiliation>VP, Oncology Clinical Development, Xencor, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wayne Saville, MD</last_name>
    <phone>858-480-3410</phone>
    <email>wsaville@xencor.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chelsea Johnson, RN</last_name>
    <phone>858-480-3891</phone>
    <email>cjohnson@xencor.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Stock, MD</last_name>
      <email>wstock@medicine.bsd.uchicago.edu</email>
    </contact>
    <contact_backup>
      <last_name>Howard Weiner</last_name>
      <phone>773-702-2084</phone>
      <email>hweiner@medicine.bsd.uchicago.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kasturi Ganesh Barki</last_name>
      <phone>614-685-6227</phone>
      <email>kasturi.ganesh@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farhad Ravandi-Kashani, MD</last_name>
      <phone>713-745-0394</phone>
      <email>fravandi@mdanderson.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 3, 2016</lastchanged_date>
  <firstreceived_date>March 31, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>B-ALL</keyword>
  <keyword>BPDCN</keyword>
  <keyword>CML</keyword>
  <keyword>Blast Crisis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Blast Crisis</mesh_term>
    <mesh_term>Burkitt Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
